445 reports of this reaction
2.5% of all BRENTUXIMAB VEDOTIN reports
#7 most reported adverse reaction
HODGKIN^S DISEASE is the #7 most commonly reported adverse reaction for BRENTUXIMAB VEDOTIN, manufactured by SEAGEN INC.. There are 445 FDA adverse event reports linking BRENTUXIMAB VEDOTIN to HODGKIN^S DISEASE. This represents approximately 2.5% of all 18,008 adverse event reports for this drug.
Patients taking BRENTUXIMAB VEDOTIN who experience hodgkin^s disease should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
HODGKIN^S DISEASE is a less commonly reported adverse event for BRENTUXIMAB VEDOTIN, but still significant enough to appear in the safety profile.
In addition to hodgkin^s disease, the following adverse reactions have been reported for BRENTUXIMAB VEDOTIN:
The following drugs have also been linked to hodgkin^s disease in FDA adverse event reports:
HODGKIN^S DISEASE has been reported as an adverse event in 445 FDA reports for BRENTUXIMAB VEDOTIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
HODGKIN^S DISEASE accounts for approximately 2.5% of all adverse event reports for BRENTUXIMAB VEDOTIN, making it a notable side effect.
If you experience hodgkin^s disease while taking BRENTUXIMAB VEDOTIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.